neuromodulation
BackgroundGastrointestinal adverse events (GI AEs) are the main dose-limiting side effects of metformin in type 2 diabetes mellitus (T2DM), reducing adherence and compromising long-term glycaemic control. Current strategies (dose adjustment or combination therapy) seldom address both tolerability and sustained metabolic efficacy. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-i…
Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with nearly 200 million people affected. While many respond well to antidepressants, psychotherapy, or neuromodulation approaches like TMS and ECT, up to 40% of patients experience little... The post Deep Brain Stimulation Offers New Hope for Treatment-Resistant Depression appeared first on Louis A. Faillac…
Dr. Xiang Qian and Dr. QiLiang Chen demonstrate the feasibility of a minimally invasive PNS technique that provides reduction in headache pain for a sustained time, even after the device is removed.
In this episode, Dr. Stavros Zanos, a renowned researcher at the Feinstein Institutes for Medical Research, discusses the potential of focused ultrasound neuromodulation in treating a wide range of cardiovascular and inflammatory diseases. Dr. Zanos explains how ultrasound activates neurons through mechanosensitive channels and shares the promising results of recent studies using neuromodulation …
Congratulations to BioE PhD alumna Kate Rosenbluth, founder of Cala Health, named to Forbes' list of "52 Women-Led Startups Driving The Future Of HealthTech And FemTech". Cala Health creates non-invasive wearable neuromodulation therapies for patients living with chronic diseases.
